nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—Isoprenaline—MAPK1—melanoma	0.00984	1	CrCbGaD
Formoterol—Dysgeusia—Vemurafenib—melanoma	0.00419	0.00529	CcSEcCtD
Formoterol—Back pain—Vemurafenib—melanoma	0.00414	0.00522	CcSEcCtD
Formoterol—Gastroenteritis—Temozolomide—melanoma	0.0041	0.00517	CcSEcCtD
Formoterol—Injury—Carmustine—melanoma	0.00409	0.00516	CcSEcCtD
Formoterol—Nasal congestion—Temozolomide—melanoma	0.00398	0.00503	CcSEcCtD
Formoterol—Cough—Vemurafenib—melanoma	0.00373	0.00471	CcSEcCtD
Formoterol—Bone disorder—Docetaxel—melanoma	0.00368	0.00465	CcSEcCtD
Formoterol—Bronchospasm—Bleomycin—melanoma	0.00366	0.00462	CcSEcCtD
Formoterol—Myalgia—Vemurafenib—melanoma	0.00364	0.0046	CcSEcCtD
Formoterol—Arthralgia—Vemurafenib—melanoma	0.00364	0.0046	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00362	0.00456	CcSEcCtD
Formoterol—Anaphylactic shock—Vemurafenib—melanoma	0.00349	0.00441	CcSEcCtD
Formoterol—Infection—Vemurafenib—melanoma	0.00347	0.00438	CcSEcCtD
Formoterol—Inflammation—Docetaxel—melanoma	0.00343	0.00433	CcSEcCtD
Formoterol—Nervous system disorder—Vemurafenib—melanoma	0.00342	0.00432	CcSEcCtD
Formoterol—Hypokalaemia—Carmustine—melanoma	0.00342	0.00431	CcSEcCtD
Formoterol—Skin disorder—Vemurafenib—melanoma	0.00339	0.00428	CcSEcCtD
Formoterol—Dehydration—Temozolomide—melanoma	0.00338	0.00426	CcSEcCtD
Formoterol—Dry skin—Temozolomide—melanoma	0.00333	0.0042	CcSEcCtD
Formoterol—Blood pressure increased—Docetaxel—melanoma	0.00333	0.0042	CcSEcCtD
Formoterol—Hypokalaemia—Temozolomide—melanoma	0.0033	0.00417	CcSEcCtD
Formoterol—Acute coronary syndrome—Bleomycin—melanoma	0.00327	0.00413	CcSEcCtD
Formoterol—Hypotension—Vemurafenib—melanoma	0.00326	0.00412	CcSEcCtD
Formoterol—Myocardial infarction—Bleomycin—melanoma	0.00325	0.0041	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00318	0.00401	CcSEcCtD
Formoterol—Candida infection—Docetaxel—melanoma	0.00317	0.00401	CcSEcCtD
Formoterol—Haematuria—Bleomycin—melanoma	0.00316	0.00399	CcSEcCtD
Formoterol—Bronchitis—Temozolomide—melanoma	0.00302	0.00381	CcSEcCtD
Formoterol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00301	0.0038	CcSEcCtD
Formoterol—Fatigue—Vemurafenib—melanoma	0.00301	0.0038	CcSEcCtD
Formoterol—Neoplasm—Docetaxel—melanoma	0.00301	0.00379	CcSEcCtD
Formoterol—Constipation—Vemurafenib—melanoma	0.00299	0.00377	CcSEcCtD
Formoterol—Hyperglycaemia—Carmustine—melanoma	0.00293	0.0037	CcSEcCtD
Formoterol—Upper respiratory tract infection—Temozolomide—melanoma	0.00292	0.00368	CcSEcCtD
Formoterol—Hyperglycaemia—Temozolomide—melanoma	0.00283	0.00357	CcSEcCtD
Formoterol—Urinary tract infection—Carmustine—melanoma	0.00281	0.00355	CcSEcCtD
Formoterol—Body temperature increased—Vemurafenib—melanoma	0.00276	0.00348	CcSEcCtD
Formoterol—Pharyngitis—Dactinomycin—melanoma	0.00276	0.00348	CcSEcCtD
Formoterol—Urinary tract infection—Temozolomide—melanoma	0.00272	0.00343	CcSEcCtD
Formoterol—Cardiac failure congestive—Docetaxel—melanoma	0.00266	0.00336	CcSEcCtD
Formoterol—Sinusitis—Temozolomide—melanoma	0.00262	0.00331	CcSEcCtD
Formoterol—Hypersensitivity—Vemurafenib—melanoma	0.00257	0.00325	CcSEcCtD
Formoterol—Oedema peripheral—Carmustine—melanoma	0.00256	0.00323	CcSEcCtD
Formoterol—Connective tissue disorder—Carmustine—melanoma	0.00255	0.00322	CcSEcCtD
Formoterol—Atrial fibrillation—Docetaxel—melanoma	0.00255	0.00321	CcSEcCtD
Formoterol—Asthenia—Vemurafenib—melanoma	0.0025	0.00316	CcSEcCtD
Formoterol—Visual impairment—Carmustine—melanoma	0.0025	0.00316	CcSEcCtD
Formoterol—Pharyngitis—Temozolomide—melanoma	0.00249	0.00315	CcSEcCtD
Formoterol—Urinary tract disorder—Temozolomide—melanoma	0.00248	0.00313	CcSEcCtD
Formoterol—Oedema peripheral—Temozolomide—melanoma	0.00247	0.00312	CcSEcCtD
Formoterol—Pruritus—Vemurafenib—melanoma	0.00247	0.00312	CcSEcCtD
Formoterol—Connective tissue disorder—Temozolomide—melanoma	0.00247	0.00311	CcSEcCtD
Formoterol—Urethral disorder—Temozolomide—melanoma	0.00246	0.00311	CcSEcCtD
Formoterol—Visual impairment—Temozolomide—melanoma	0.00242	0.00305	CcSEcCtD
Formoterol—Ill-defined disorder—Bleomycin—melanoma	0.0024	0.00303	CcSEcCtD
Formoterol—Diarrhoea—Vemurafenib—melanoma	0.00239	0.00301	CcSEcCtD
Formoterol—Malaise—Bleomycin—melanoma	0.00234	0.00295	CcSEcCtD
Formoterol—Cardiac disorder—Temozolomide—melanoma	0.00233	0.00294	CcSEcCtD
Formoterol—Arrhythmia—Carmustine—melanoma	0.00232	0.00293	CcSEcCtD
Formoterol—Dizziness—Vemurafenib—melanoma	0.00231	0.00291	CcSEcCtD
Formoterol—Mental disorder—Carmustine—melanoma	0.00228	0.00287	CcSEcCtD
Formoterol—Immune system disorder—Temozolomide—melanoma	0.00227	0.00286	CcSEcCtD
Formoterol—Mediastinal disorder—Temozolomide—melanoma	0.00226	0.00286	CcSEcCtD
Formoterol—Malnutrition—Carmustine—melanoma	0.00226	0.00285	CcSEcCtD
Formoterol—Cough—Bleomycin—melanoma	0.00226	0.00285	CcSEcCtD
Formoterol—Dehydration—Docetaxel—melanoma	0.00224	0.00283	CcSEcCtD
Formoterol—Ill-defined disorder—Dactinomycin—melanoma	0.00224	0.00283	CcSEcCtD
Formoterol—Vomiting—Vemurafenib—melanoma	0.00222	0.0028	CcSEcCtD
Formoterol—Dry skin—Docetaxel—melanoma	0.00221	0.00279	CcSEcCtD
Formoterol—Myalgia—Bleomycin—melanoma	0.00221	0.00278	CcSEcCtD
Formoterol—Chest pain—Bleomycin—melanoma	0.00221	0.00278	CcSEcCtD
Formoterol—Rash—Vemurafenib—melanoma	0.0022	0.00278	CcSEcCtD
Formoterol—Mental disorder—Temozolomide—melanoma	0.0022	0.00278	CcSEcCtD
Formoterol—Dermatitis—Vemurafenib—melanoma	0.0022	0.00278	CcSEcCtD
Formoterol—Back pain—Carmustine—melanoma	0.00219	0.00276	CcSEcCtD
Formoterol—Headache—Vemurafenib—melanoma	0.00219	0.00276	CcSEcCtD
Formoterol—Malnutrition—Temozolomide—melanoma	0.00219	0.00276	CcSEcCtD
Formoterol—Discomfort—Bleomycin—melanoma	0.00218	0.00275	CcSEcCtD
Formoterol—Malaise—Dactinomycin—melanoma	0.00218	0.00275	CcSEcCtD
Formoterol—Cramp muscle—Docetaxel—melanoma	0.00217	0.00274	CcSEcCtD
Formoterol—Nasopharyngitis—Docetaxel—melanoma	0.00216	0.00272	CcSEcCtD
Formoterol—Dysgeusia—Temozolomide—melanoma	0.00214	0.0027	CcSEcCtD
Formoterol—Tremor—Carmustine—melanoma	0.00212	0.00267	CcSEcCtD
Formoterol—Oedema—Bleomycin—melanoma	0.00212	0.00267	CcSEcCtD
Formoterol—Anaphylactic shock—Bleomycin—melanoma	0.00212	0.00267	CcSEcCtD
Formoterol—Back pain—Temozolomide—melanoma	0.00211	0.00267	CcSEcCtD
Formoterol—Infection—Bleomycin—melanoma	0.0021	0.00265	CcSEcCtD
Formoterol—Agitation—Carmustine—melanoma	0.00208	0.00262	CcSEcCtD
Formoterol—Nausea—Vemurafenib—melanoma	0.00207	0.00262	CcSEcCtD
Formoterol—Myalgia—Dactinomycin—melanoma	0.00206	0.0026	CcSEcCtD
Formoterol—Bronchospasm—Docetaxel—melanoma	0.00205	0.00259	CcSEcCtD
Formoterol—Tremor—Temozolomide—melanoma	0.00205	0.00258	CcSEcCtD
Formoterol—Discomfort—Dactinomycin—melanoma	0.00203	0.00257	CcSEcCtD
Formoterol—Angina pectoris—Docetaxel—melanoma	0.00203	0.00256	CcSEcCtD
Formoterol—Ill-defined disorder—Temozolomide—melanoma	0.00203	0.00256	CcSEcCtD
Formoterol—Agitation—Temozolomide—melanoma	0.00201	0.00254	CcSEcCtD
Formoterol—Angioedema—Temozolomide—melanoma	0.002	0.00252	CcSEcCtD
Formoterol—Hypotension—Bleomycin—melanoma	0.00198	0.00249	CcSEcCtD
Formoterol—Oedema—Dactinomycin—melanoma	0.00197	0.00249	CcSEcCtD
Formoterol—Malaise—Temozolomide—melanoma	0.00197	0.00249	CcSEcCtD
Formoterol—Infection—Dactinomycin—melanoma	0.00196	0.00247	CcSEcCtD
Formoterol—Hypertension—Carmustine—melanoma	0.00195	0.00246	CcSEcCtD
Formoterol—Palpitations—Temozolomide—melanoma	0.00193	0.00244	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00193	0.00243	CcSEcCtD
Formoterol—Chest pain—Carmustine—melanoma	0.00193	0.00243	CcSEcCtD
Formoterol—Myalgia—Carmustine—melanoma	0.00193	0.00243	CcSEcCtD
Formoterol—Anxiety—Carmustine—melanoma	0.00192	0.00242	CcSEcCtD
Formoterol—Cough—Temozolomide—melanoma	0.00191	0.00241	CcSEcCtD
Formoterol—Hypertension—Temozolomide—melanoma	0.00189	0.00238	CcSEcCtD
Formoterol—Dyspnoea—Bleomycin—melanoma	0.00189	0.00238	CcSEcCtD
Formoterol—Myalgia—Temozolomide—melanoma	0.00186	0.00235	CcSEcCtD
Formoterol—Arthralgia—Temozolomide—melanoma	0.00186	0.00235	CcSEcCtD
Formoterol—Anxiety—Temozolomide—melanoma	0.00185	0.00234	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00185	0.00233	CcSEcCtD
Formoterol—Oedema—Carmustine—melanoma	0.00185	0.00233	CcSEcCtD
Formoterol—Discomfort—Temozolomide—melanoma	0.00184	0.00232	CcSEcCtD
Formoterol—Infection—Carmustine—melanoma	0.00183	0.00231	CcSEcCtD
Formoterol—Acute coronary syndrome—Docetaxel—melanoma	0.00183	0.00231	CcSEcCtD
Formoterol—Myocardial infarction—Docetaxel—melanoma	0.00182	0.0023	CcSEcCtD
Formoterol—Dry mouth—Temozolomide—melanoma	0.00182	0.0023	CcSEcCtD
Formoterol—Pain—Bleomycin—melanoma	0.00181	0.00228	CcSEcCtD
Formoterol—Conjunctivitis—Docetaxel—melanoma	0.00181	0.00228	CcSEcCtD
Formoterol—Tachycardia—Carmustine—melanoma	0.0018	0.00227	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0018	0.00227	CcSEcCtD
Formoterol—Oedema—Temozolomide—melanoma	0.00178	0.00225	CcSEcCtD
Formoterol—Anaphylactic shock—Temozolomide—melanoma	0.00178	0.00225	CcSEcCtD
Formoterol—Infection—Temozolomide—melanoma	0.00177	0.00224	CcSEcCtD
Formoterol—Nervous system disorder—Temozolomide—melanoma	0.00175	0.00221	CcSEcCtD
Formoterol—Feeling abnormal—Bleomycin—melanoma	0.00174	0.0022	CcSEcCtD
Formoterol—Skin disorder—Temozolomide—melanoma	0.00173	0.00219	CcSEcCtD
Formoterol—Hypotension—Carmustine—melanoma	0.00173	0.00218	CcSEcCtD
Formoterol—Fatigue—Dactinomycin—melanoma	0.0017	0.00215	CcSEcCtD
Formoterol—Pain—Dactinomycin—melanoma	0.00169	0.00213	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Carmustine—melanoma	0.00168	0.00212	CcSEcCtD
Formoterol—Urticaria—Bleomycin—melanoma	0.00168	0.00212	CcSEcCtD
Formoterol—Rhinitis—Docetaxel—melanoma	0.00167	0.00211	CcSEcCtD
Formoterol—Body temperature increased—Bleomycin—melanoma	0.00167	0.00211	CcSEcCtD
Formoterol—Insomnia—Carmustine—melanoma	0.00167	0.00211	CcSEcCtD
Formoterol—Pharyngitis—Docetaxel—melanoma	0.00166	0.00209	CcSEcCtD
Formoterol—Urinary tract disorder—Docetaxel—melanoma	0.00165	0.00208	CcSEcCtD
Formoterol—Dyspnoea—Carmustine—melanoma	0.00165	0.00208	CcSEcCtD
Formoterol—Oedema peripheral—Docetaxel—melanoma	0.00165	0.00208	CcSEcCtD
Formoterol—Somnolence—Carmustine—melanoma	0.00164	0.00207	CcSEcCtD
Formoterol—Connective tissue disorder—Docetaxel—melanoma	0.00164	0.00207	CcSEcCtD
Formoterol—Urethral disorder—Docetaxel—melanoma	0.00164	0.00207	CcSEcCtD
Formoterol—Feeling abnormal—Dactinomycin—melanoma	0.00163	0.00205	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Temozolomide—melanoma	0.00163	0.00205	CcSEcCtD
Formoterol—Insomnia—Temozolomide—melanoma	0.00161	0.00204	CcSEcCtD
Formoterol—Gastrointestinal pain—Dactinomycin—melanoma	0.00161	0.00204	CcSEcCtD
Formoterol—Visual impairment—Docetaxel—melanoma	0.00161	0.00203	CcSEcCtD
Formoterol—Gastrointestinal disorder—Carmustine—melanoma	0.00159	0.00201	CcSEcCtD
Formoterol—Dyspnoea—Temozolomide—melanoma	0.00159	0.00201	CcSEcCtD
Formoterol—Somnolence—Temozolomide—melanoma	0.00159	0.002	CcSEcCtD
Formoterol—Pain—Carmustine—melanoma	0.00158	0.00199	CcSEcCtD
Formoterol—Constipation—Carmustine—melanoma	0.00158	0.00199	CcSEcCtD
Formoterol—Dyspepsia—Temozolomide—melanoma	0.00157	0.00198	CcSEcCtD
Formoterol—Abdominal pain—Dactinomycin—melanoma	0.00156	0.00197	CcSEcCtD
Formoterol—Body temperature increased—Dactinomycin—melanoma	0.00156	0.00197	CcSEcCtD
Formoterol—Hypersensitivity—Bleomycin—melanoma	0.00156	0.00197	CcSEcCtD
Formoterol—Cardiac disorder—Docetaxel—melanoma	0.00155	0.00196	CcSEcCtD
Formoterol—Gastrointestinal disorder—Temozolomide—melanoma	0.00154	0.00194	CcSEcCtD
Formoterol—Fatigue—Temozolomide—melanoma	0.00154	0.00194	CcSEcCtD
Formoterol—Pain—Temozolomide—melanoma	0.00153	0.00193	CcSEcCtD
Formoterol—Constipation—Temozolomide—melanoma	0.00153	0.00193	CcSEcCtD
Formoterol—Feeling abnormal—Carmustine—melanoma	0.00152	0.00192	CcSEcCtD
Formoterol—Asthenia—Bleomycin—melanoma	0.00152	0.00191	CcSEcCtD
Formoterol—Gastrointestinal pain—Carmustine—melanoma	0.00151	0.00191	CcSEcCtD
Formoterol—Immune system disorder—Docetaxel—melanoma	0.00151	0.0019	CcSEcCtD
Formoterol—Mediastinal disorder—Docetaxel—melanoma	0.00151	0.0019	CcSEcCtD
Formoterol—Pruritus—Bleomycin—melanoma	0.0015	0.00189	CcSEcCtD
Formoterol—Arrhythmia—Docetaxel—melanoma	0.00149	0.00188	CcSEcCtD
Formoterol—Feeling abnormal—Temozolomide—melanoma	0.00147	0.00186	CcSEcCtD
Formoterol—Mental disorder—Docetaxel—melanoma	0.00146	0.00185	CcSEcCtD
Formoterol—Body temperature increased—Carmustine—melanoma	0.00146	0.00184	CcSEcCtD
Formoterol—Abdominal pain—Carmustine—melanoma	0.00146	0.00184	CcSEcCtD
Formoterol—Gastrointestinal pain—Temozolomide—melanoma	0.00146	0.00184	CcSEcCtD
Formoterol—Malnutrition—Docetaxel—melanoma	0.00145	0.00183	CcSEcCtD
Formoterol—Hypersensitivity—Dactinomycin—melanoma	0.00145	0.00183	CcSEcCtD
Formoterol—Dysgeusia—Docetaxel—melanoma	0.00142	0.0018	CcSEcCtD
Formoterol—Urticaria—Temozolomide—melanoma	0.00142	0.00179	CcSEcCtD
Formoterol—Asthenia—Dactinomycin—melanoma	0.00142	0.00179	CcSEcCtD
Formoterol—Abdominal pain—Temozolomide—melanoma	0.00141	0.00178	CcSEcCtD
Formoterol—Body temperature increased—Temozolomide—melanoma	0.00141	0.00178	CcSEcCtD
Formoterol—Back pain—Docetaxel—melanoma	0.00141	0.00177	CcSEcCtD
Formoterol—Muscle spasms—Docetaxel—melanoma	0.0014	0.00176	CcSEcCtD
Formoterol—Hypersensitivity—Carmustine—melanoma	0.00136	0.00172	CcSEcCtD
Formoterol—Diarrhoea—Dactinomycin—melanoma	0.00135	0.0017	CcSEcCtD
Formoterol—Vomiting—Bleomycin—melanoma	0.00134	0.0017	CcSEcCtD
Formoterol—Rash—Bleomycin—melanoma	0.00133	0.00168	CcSEcCtD
Formoterol—Dermatitis—Bleomycin—melanoma	0.00133	0.00168	CcSEcCtD
Formoterol—Asthenia—Carmustine—melanoma	0.00132	0.00167	CcSEcCtD
Formoterol—Hypersensitivity—Temozolomide—melanoma	0.00131	0.00166	CcSEcCtD
Formoterol—Palpitations—Docetaxel—melanoma	0.00128	0.00162	CcSEcCtD
Formoterol—Asthenia—Temozolomide—melanoma	0.00128	0.00162	CcSEcCtD
Formoterol—Cough—Docetaxel—melanoma	0.00127	0.0016	CcSEcCtD
Formoterol—Diarrhoea—Carmustine—melanoma	0.00126	0.00159	CcSEcCtD
Formoterol—Pruritus—Temozolomide—melanoma	0.00126	0.00159	CcSEcCtD
Formoterol—Nausea—Bleomycin—melanoma	0.00126	0.00159	CcSEcCtD
Formoterol—Hypertension—Docetaxel—melanoma	0.00126	0.00158	CcSEcCtD
Formoterol—Vomiting—Dactinomycin—melanoma	0.00125	0.00158	CcSEcCtD
Formoterol—Rash—Dactinomycin—melanoma	0.00124	0.00157	CcSEcCtD
Formoterol—Arthralgia—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Formoterol—Chest pain—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Formoterol—Myalgia—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00123	0.00155	CcSEcCtD
Formoterol—Dizziness—Carmustine—melanoma	0.00122	0.00154	CcSEcCtD
Formoterol—Diarrhoea—Temozolomide—melanoma	0.00122	0.00154	CcSEcCtD
Formoterol—Dry mouth—Docetaxel—melanoma	0.00121	0.00153	CcSEcCtD
Formoterol—Anaphylactic shock—Docetaxel—melanoma	0.00119	0.0015	CcSEcCtD
Formoterol—Oedema—Docetaxel—melanoma	0.00119	0.0015	CcSEcCtD
Formoterol—Dizziness—Temozolomide—melanoma	0.00118	0.00149	CcSEcCtD
Formoterol—Infection—Docetaxel—melanoma	0.00118	0.00149	CcSEcCtD
Formoterol—Vomiting—Carmustine—melanoma	0.00117	0.00148	CcSEcCtD
Formoterol—Nausea—Dactinomycin—melanoma	0.00117	0.00148	CcSEcCtD
Formoterol—Rash—Carmustine—melanoma	0.00116	0.00147	CcSEcCtD
Formoterol—Nervous system disorder—Docetaxel—melanoma	0.00116	0.00147	CcSEcCtD
Formoterol—Dermatitis—Carmustine—melanoma	0.00116	0.00147	CcSEcCtD
Formoterol—Tachycardia—Docetaxel—melanoma	0.00116	0.00146	CcSEcCtD
Formoterol—Headache—Carmustine—melanoma	0.00116	0.00146	CcSEcCtD
Formoterol—Skin disorder—Docetaxel—melanoma	0.00115	0.00145	CcSEcCtD
Formoterol—Vomiting—Temozolomide—melanoma	0.00113	0.00143	CcSEcCtD
Formoterol—Rash—Temozolomide—melanoma	0.00112	0.00142	CcSEcCtD
Formoterol—Dermatitis—Temozolomide—melanoma	0.00112	0.00142	CcSEcCtD
Formoterol—Headache—Temozolomide—melanoma	0.00112	0.00141	CcSEcCtD
Formoterol—Hypotension—Docetaxel—melanoma	0.00111	0.0014	CcSEcCtD
Formoterol—Nausea—Carmustine—melanoma	0.0011	0.00138	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Docetaxel—melanoma	0.00108	0.00136	CcSEcCtD
Formoterol—Insomnia—Docetaxel—melanoma	0.00107	0.00135	CcSEcCtD
Formoterol—Nausea—Temozolomide—melanoma	0.00106	0.00134	CcSEcCtD
Formoterol—Dyspnoea—Docetaxel—melanoma	0.00106	0.00133	CcSEcCtD
Formoterol—Somnolence—Docetaxel—melanoma	0.00105	0.00133	CcSEcCtD
Formoterol—Dyspepsia—Docetaxel—melanoma	0.00104	0.00132	CcSEcCtD
Formoterol—Gastrointestinal disorder—Docetaxel—melanoma	0.00102	0.00129	CcSEcCtD
Formoterol—Fatigue—Docetaxel—melanoma	0.00102	0.00129	CcSEcCtD
Formoterol—Pain—Docetaxel—melanoma	0.00101	0.00128	CcSEcCtD
Formoterol—Constipation—Docetaxel—melanoma	0.00101	0.00128	CcSEcCtD
Formoterol—Feeling abnormal—Docetaxel—melanoma	0.000978	0.00123	CcSEcCtD
Formoterol—Gastrointestinal pain—Docetaxel—melanoma	0.00097	0.00122	CcSEcCtD
Formoterol—Body temperature increased—Docetaxel—melanoma	0.000938	0.00118	CcSEcCtD
Formoterol—Abdominal pain—Docetaxel—melanoma	0.000938	0.00118	CcSEcCtD
Formoterol—Hypersensitivity—Docetaxel—melanoma	0.000874	0.0011	CcSEcCtD
Formoterol—Asthenia—Docetaxel—melanoma	0.000851	0.00107	CcSEcCtD
Formoterol—Pruritus—Docetaxel—melanoma	0.000839	0.00106	CcSEcCtD
Formoterol—Diarrhoea—Docetaxel—melanoma	0.000812	0.00102	CcSEcCtD
Formoterol—Dizziness—Docetaxel—melanoma	0.000785	0.00099	CcSEcCtD
Formoterol—Vomiting—Docetaxel—melanoma	0.000754	0.000952	CcSEcCtD
Formoterol—Rash—Docetaxel—melanoma	0.000748	0.000944	CcSEcCtD
Formoterol—Dermatitis—Docetaxel—melanoma	0.000747	0.000943	CcSEcCtD
Formoterol—Headache—Docetaxel—melanoma	0.000743	0.000938	CcSEcCtD
Formoterol—Nausea—Docetaxel—melanoma	0.000705	0.000889	CcSEcCtD
Formoterol—ADRB1—Signaling Pathways—SYK—melanoma	6.54e-05	0.000331	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	6.49e-05	0.000328	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKT3—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NGFR—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ITGAV—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SYK—melanoma	6.4e-05	0.000324	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	6.35e-05	0.000321	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ITGAV—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NGFR—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKT3—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PLA2G6—melanoma	6.13e-05	0.00031	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PLA2G6—melanoma	6.07e-05	0.000307	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—VCAN—melanoma	5.98e-05	0.000303	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SOCS1—melanoma	5.95e-05	0.000301	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	5.93e-05	0.0003	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—S100B—melanoma	5.93e-05	0.0003	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	5.89e-05	0.000298	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SOCS1—melanoma	5.82e-05	0.000294	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	5.8e-05	0.000294	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—S100B—melanoma	5.8e-05	0.000293	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	5.76e-05	0.000292	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ABCB1—melanoma	5.74e-05	0.00029	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB4—melanoma	5.67e-05	0.000287	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.66e-05	0.000286	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	5.66e-05	0.000286	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN2B—melanoma	5.62e-05	0.000284	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB4—melanoma	5.55e-05	0.000281	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	5.53e-05	0.00028	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—VCAN—melanoma	5.5e-05	0.000278	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN2B—melanoma	5.5e-05	0.000278	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.47e-05	0.000276	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—VCAN—melanoma	5.46e-05	0.000276	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD86—melanoma	5.44e-05	0.000275	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	5.44e-05	0.000275	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EDN1—melanoma	5.4e-05	0.000273	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD86—melanoma	5.32e-05	0.000269	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	5.32e-05	0.000269	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PRKCA—melanoma	5.28e-05	0.000267	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EDN1—melanoma	5.28e-05	0.000267	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CSF2—melanoma	5.27e-05	0.000267	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF1—melanoma	5.27e-05	0.000267	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ERCC2—melanoma	5.24e-05	0.000265	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2—melanoma	5.19e-05	0.000263	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—E2F1—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF1—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CSF2—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	5.14e-05	0.00026	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDGFRA—melanoma	5.11e-05	0.000258	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2—melanoma	5.08e-05	0.000257	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ITGB3—melanoma	5.06e-05	0.000256	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PRKCA—melanoma	5.06e-05	0.000256	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP17A1—melanoma	5.05e-05	0.000255	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—E2F1—melanoma	5.05e-05	0.000255	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	5.02e-05	0.000254	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDGFRA—melanoma	5e-05	0.000253	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.98e-05	0.000252	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.98e-05	0.000252	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SPP1—melanoma	4.96e-05	0.000251	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ITGB3—melanoma	4.95e-05	0.00025	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PRKCA—melanoma	4.95e-05	0.00025	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAP2K2—melanoma	4.94e-05	0.00025	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL8—melanoma	4.94e-05	0.00025	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	4.92e-05	0.000249	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SPP1—melanoma	4.85e-05	0.000245	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAP2K2—melanoma	4.83e-05	0.000245	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL8—melanoma	4.83e-05	0.000244	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GNA11—melanoma	4.77e-05	0.000241	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—melanoma	4.72e-05	0.000239	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TERT—melanoma	4.7e-05	0.000238	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RAC1—melanoma	4.69e-05	0.000237	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—FASN—melanoma	4.67e-05	0.000236	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP17A1—melanoma	4.64e-05	0.000235	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—melanoma	4.61e-05	0.000233	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP17A1—melanoma	4.6e-05	0.000233	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TERT—melanoma	4.6e-05	0.000233	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC5A5—melanoma	4.59e-05	0.000232	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RAC1—melanoma	4.59e-05	0.000232	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.54e-05	0.00023	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HIF1A—melanoma	4.5e-05	0.000227	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.48e-05	0.000227	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GNAQ—melanoma	4.43e-05	0.000224	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CD44—melanoma	4.43e-05	0.000224	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HIF1A—melanoma	4.4e-05	0.000222	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GNA11—melanoma	4.39e-05	0.000222	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GNA11—melanoma	4.35e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.34e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.3e-05	0.000218	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KDR—melanoma	4.3e-05	0.000217	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—FASN—melanoma	4.29e-05	0.000217	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—FASN—melanoma	4.25e-05	0.000215	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1B1—melanoma	4.25e-05	0.000215	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC5A5—melanoma	4.22e-05	0.000213	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KDR—melanoma	4.21e-05	0.000213	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC5A5—melanoma	4.18e-05	0.000212	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FN1—melanoma	4.14e-05	0.000209	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CG—melanoma	4.14e-05	0.000209	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CD44—melanoma	4.08e-05	0.000206	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GNAQ—melanoma	4.08e-05	0.000206	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOTCH1—melanoma	4.05e-05	0.000205	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FN1—melanoma	4.05e-05	0.000205	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GNAQ—melanoma	4.04e-05	0.000204	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CD44—melanoma	4.04e-05	0.000204	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PPARG—melanoma	3.99e-05	0.000202	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CD80—melanoma	3.97e-05	0.000201	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOTCH1—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KIT—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—APC—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CG—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—NRAS—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.92e-05	0.000198	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGF—melanoma	3.91e-05	0.000198	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1B1—melanoma	3.91e-05	0.000198	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CD80—melanoma	3.88e-05	0.000196	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1B1—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CG—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—APC—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KIT—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—NRAS—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGF—melanoma	3.83e-05	0.000194	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK3—melanoma	3.79e-05	0.000192	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.75e-05	0.00019	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BRAF—melanoma	3.72e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK3—melanoma	3.71e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BRAF—melanoma	3.64e-05	0.000184	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CD—melanoma	3.64e-05	0.000184	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1—melanoma	3.63e-05	0.000183	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK1—melanoma	3.61e-05	0.000183	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—EGFR—melanoma	3.61e-05	0.000182	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALB—melanoma	3.59e-05	0.000182	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1—melanoma	3.55e-05	0.000179	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK1—melanoma	3.53e-05	0.000179	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—EGFR—melanoma	3.53e-05	0.000179	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAP2K1—melanoma	3.5e-05	0.000177	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ABCB1—melanoma	3.5e-05	0.000177	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CD—melanoma	3.48e-05	0.000176	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	3.45e-05	0.000174	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAP2K1—melanoma	3.43e-05	0.000173	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.42e-05	0.000173	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—KRAS—melanoma	3.41e-05	0.000172	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CD—melanoma	3.41e-05	0.000172	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	3.37e-05	0.000171	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—KRAS—melanoma	3.33e-05	0.000169	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF2—melanoma	3.33e-05	0.000169	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF2—melanoma	3.26e-05	0.000165	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PRKCA—melanoma	3.22e-05	0.000163	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ABCB1—melanoma	3.22e-05	0.000163	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ERCC2—melanoma	3.19e-05	0.000162	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ABCB1—melanoma	3.19e-05	0.000161	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CB—melanoma	3.17e-05	0.00016	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—melanoma	3.14e-05	0.000159	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	3.13e-05	0.000158	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MDM2—melanoma	3.12e-05	0.000158	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB2—melanoma	3.07e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	3.06e-05	0.000155	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MDM2—melanoma	3.05e-05	0.000154	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CB—melanoma	3.03e-05	0.000153	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB2—melanoma	3.01e-05	0.000152	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CB—melanoma	2.97e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PRKCA—melanoma	2.96e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ERCC2—melanoma	2.94e-05	0.000149	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PRKCA—melanoma	2.94e-05	0.000149	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL8—melanoma	2.92e-05	0.000147	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ERCC2—melanoma	2.91e-05	0.000147	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HRAS—melanoma	2.9e-05	0.000147	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL8—melanoma	2.85e-05	0.000144	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1B—melanoma	2.85e-05	0.000144	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HRAS—melanoma	2.83e-05	0.000143	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—AKT1—melanoma	2.82e-05	0.000142	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CASP3—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1B—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—melanoma	2.77e-05	0.00014	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—AKT1—melanoma	2.76e-05	0.000139	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTEN—melanoma	2.74e-05	0.000139	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CASP3—melanoma	2.73e-05	0.000138	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—melanoma	2.73e-05	0.000138	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—melanoma	2.72e-05	0.000137	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—melanoma	2.71e-05	0.000137	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CTNNB1—melanoma	2.69e-05	0.000136	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—melanoma	2.66e-05	0.000134	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.65e-05	0.000134	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MMP9—melanoma	2.64e-05	0.000133	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CTNNB1—melanoma	2.63e-05	0.000133	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1A—melanoma	2.63e-05	0.000133	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTEN—melanoma	2.62e-05	0.000133	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NFKB1—melanoma	2.61e-05	0.000132	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MMP9—melanoma	2.58e-05	0.00013	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1A—melanoma	2.57e-05	0.00013	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTEN—melanoma	2.57e-05	0.00013	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—AKT1—melanoma	2.56e-05	0.000129	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NFKB1—melanoma	2.55e-05	0.000129	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CG—melanoma	2.52e-05	0.000128	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—AKT1—melanoma	2.5e-05	0.000127	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPARG—melanoma	2.43e-05	0.000123	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.41e-05	0.000122	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—melanoma	2.37e-05	0.00012	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STAT3—melanoma	2.35e-05	0.000119	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NRAS—melanoma	2.34e-05	0.000118	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CG—melanoma	2.32e-05	0.000117	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—melanoma	2.32e-05	0.000117	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CG—melanoma	2.3e-05	0.000116	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STAT3—melanoma	2.29e-05	0.000116	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NRAS—melanoma	2.29e-05	0.000116	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK3—melanoma	2.24e-05	0.000113	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPARG—melanoma	2.24e-05	0.000113	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPARG—melanoma	2.22e-05	0.000112	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CD—melanoma	2.22e-05	0.000112	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK3—melanoma	2.19e-05	0.000111	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALB—melanoma	2.19e-05	0.000111	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—melanoma	2.18e-05	0.00011	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK1—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGFR—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK1—melanoma	2.09e-05	0.000105	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGFR—melanoma	2.08e-05	0.000105	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CD—melanoma	2.04e-05	0.000103	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CD—melanoma	2.02e-05	0.000102	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KRAS—melanoma	2.01e-05	0.000102	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALB—melanoma	2.01e-05	0.000102	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALB—melanoma	2e-05	0.000101	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KRAS—melanoma	1.97e-05	9.96e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CB—melanoma	1.93e-05	9.78e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CA—melanoma	1.93e-05	9.77e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—melanoma	1.92e-05	9.69e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CA—melanoma	1.85e-05	9.36e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CA—melanoma	1.81e-05	9.15e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—melanoma	1.79e-05	9.05e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CB—melanoma	1.78e-05	8.99e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CB—melanoma	1.76e-05	8.91e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—melanoma	1.76e-05	8.91e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—melanoma	1.75e-05	8.85e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—melanoma	1.75e-05	8.83e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HRAS—melanoma	1.71e-05	8.66e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HRAS—melanoma	1.67e-05	8.47e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTEN—melanoma	1.67e-05	8.45e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—melanoma	1.64e-05	8.28e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—melanoma	1.6e-05	8.1e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—AKT1—melanoma	1.58e-05	7.98e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTEN—melanoma	1.54e-05	7.77e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTEN—melanoma	1.52e-05	7.7e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKT1—melanoma	1.51e-05	7.64e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKT1—melanoma	1.48e-05	7.48e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CA—melanoma	1.18e-05	5.96e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CA—melanoma	1.08e-05	5.48e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CA—melanoma	1.07e-05	5.43e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKT1—melanoma	9.63e-06	4.87e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKT1—melanoma	8.85e-06	4.48e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKT1—melanoma	8.78e-06	4.44e-05	CbGpPWpGaD
